| 5.43 0.69 (14.56%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.38  |
1-year : | 7.46 |
| Resists | First : | 5.46 |
Second : | 6.38 |
| Pivot price | 3.66 |
|||
| Supports | First : | 3.64 |
Second : | 2.51 |
| MAs | MA(5) : | 4.43 |
MA(20) : | 3.46 |
| MA(100) : | 2.77 |
MA(250) : | 4.23  |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 93.8 |
D(3) : | 78.3 |
| RSI | RSI(14): 77.4 |
|||
| 52-week | High : | 15.52 | Low : | 1.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EVAX ] has closed above the upper band by 6.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 262.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.48 - 5.5 | 5.5 - 5.52 |
| Low: | 4.66 - 4.68 | 4.68 - 4.7 |
| Close: | 5.39 - 5.43 | 5.43 - 5.47 |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Sun, 31 Aug 2025
Evaxion Biotech A/S Adr Earnings Call: Strategic Growth Amid Challenges - TipRanks
Tue, 04 Feb 2025
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Tue, 04 Feb 2025
Evaxion Biotech’s Dramatic Surge: What’s Next? - StocksToTrade
Fri, 31 Jan 2025
Major Pharma Giant's VC Fund Doubles Down on Evaxion Biotech in $10.8M Strategic Round - Stock Titan
Fri, 10 Jan 2025
Evaxion Biotech A/S Announces Revised Effective Date for Change in American Depositary Shares Ratio - Nasdaq
Mon, 30 Dec 2024
Evaxion Biotech A/S Announces Change in American Depositary Shares Ratio to Enhance Liquidity - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.7729e+008 (%) |
| Held by Institutions | 23 (%) |
| Shares Short | 125 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.362e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -11 % |
| Return on Assets (ttm) | 729.7 % |
| Return on Equity (ttm) | -46.4 % |
| Qtrly Rev. Growth | 3.18e+006 % |
| Gross Profit (p.s.) | -330.44 |
| Sales Per Share | -1392.18 |
| EBITDA (p.s.) | 1.38261e+007 |
| Qtrly Earnings Growth | -6.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.26 |
| Dividend | 0 |
| Forward Dividend | 153250 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|